CD4+CD28null T cells

There are 6 papers on CD4+CD28null T cells in aging research: 1 trial and 4 observational studies in people, 1 review.

Biomarker

6 papers study it3 more mention it9 findings

See all 9 papers on CD4+CD28null T cells

“At baseline, hyperuricemic patients had more CD4+CD28null/CD4+ cells than normouricemic subjects (36.8% vs. 6.1%; p = 0.001)”
Senescent CD4⁺CD28null cells are increased in chronic hyperuricemia, show aberrant effector phenotypes, and are reversed after allopurinol therapy: a proof-of-concept pilot studyClinical rheumatology2023doi:10.1007/s10067-023-06595-8
  • Human trial1
  • Humans4

Interventions

1

Allopurinol

downin humans1

1 study
  1. Allopurinol decreases CD4+CD28null T cells in humans (chronic hyperuricemia) (from 36.8% (23.0-43.7) to 15.8% (4.7-28.1)).

    “CD4+CD28null cells decreased from 36.8% (23.0-43.7) to 15.8% (4.7-28.1; p = 0.031).”

    Human trialchronic hyperuricemiaoralblood150 mg/day for 4 weeks, followed by 300 mg/day through week 1212 weeksn = 6

    Senescent CD4⁺CD28null cells are increased in chronic hyperuricemia, show aberrant effector phenotypes, and are reversed after allopurinol therapy: a proof-of-concept pilot study

    Clinical rheumatology

More on Allopurinol

Upstream

2

Coronary sinus vs vena cava

no changein humans1

1 study
  1. coronary sinus vs vena cava was not clearly linked with CD4+CD28null T cells in humans (coronary sinus vs vena cava in STEMI).

    “no significant differences were detected in CD4+CD28null cells between coronary sinus and vena cava”

    Humanscoronary sinus vs vena cava in STEMIbloodn = 24

    Senescent CD4+ T-Cell Phenotypes and Inflammatory Milieu in the Coronary and Systemic Circulation in ST-Elevation Myocardial Infarction: An Exploratory Study

    Journal of vascular research

ST-elevation myocardial infarction

upin humans1

1 study
  1. ST-elevation myocardial infarction is linked with higher CD4+CD28null T cells in humans (STEMI vs controls) (20.1 vs. 6.1%).

    “alongside an increased proportion of CD4+ cells lacking CD28 expression (20.1 vs. 6.1%).”

    HumansSTEMI vs controlsblood

    Senescent CD4+ T-Cell Phenotypes and Inflammatory Milieu in the Coronary and Systemic Circulation in ST-Elevation Myocardial Infarction: An Exploratory Study

    Journal of vascular research

More on ST-elevation myocardial infarction

Associations

6

Flow-mediated dilation

downin humans1

1 study
  1. CD4+CD28null T cells are associated with flow-mediated dilation in humans (R = -.422, p < .001).

    “negative correlations were demonstrated between the FMD with CD4+CD57+ (R = -.236, p = .023), CD8+CD57+ (R = -.409, p < .001), CD4+CD28null (R = -.422, p < .001), and CD8+CD28null (R = -.318, p = .003).”

    Humansfemales

    T-cell senescence was correlated with early atherosclerosis in patients with systemic lupus erythematosus

    International journal of rheumatic diseases

Carotid intima-media thickness

upin humans1

1 study
  1. CD4+CD28null T cells are associated with carotid intima-media thickness in humans (R = .448, p < .001).

    “Positive correlations were shown between cIMT with the CD4+CD57+ (R = .301, p = .005), CD4+CD28null (R = .448, p < .001), and CD8+CD28null (R = .422, p < .001).”

    Humansfemales

    T-cell senescence was correlated with early atherosclerosis in patients with systemic lupus erythematosus

    International journal of rheumatic diseases

More on Carotid intima-media thickness

Hyperuricemia

upin humans1

1 study
  1. Hyperuricemia is associated with CD4+CD28null T cells in humans (normouricemic controls comparison at baseline) (36.8% vs. 6.1%).

    “At baseline, hyperuricemic patients had more CD4+CD28null/CD4+ cells than normouricemic subjects (36.8% vs. 6.1%; p = 0.001)”

    Human trialnormouricemic controls comparison at baselineblood

    Senescent CD4⁺CD28null cells are increased in chronic hyperuricemia, show aberrant effector phenotypes, and are reversed after allopurinol therapy: a proof-of-concept pilot study

    Clinical rheumatology

More on Hyperuricemia

Vascular calcifications

upin humans1

1 study
  1. CD4+CD28null T cells are associated with vascular calcifications in chronic kidney disease.

    “increases in CD4+CD28null were associated with overt vascular thickening and calcification.”

    Humansin chronic kidney disease

    Novel Immune Cell Subsets Exhibit Different Associations With Vascular Outcomes in Chronic Kidney Disease Patients-Identifying Potential Biomarkers

    Frontiers in medicine

More on Vascular calcifications

Chronic kidney disease

upin humans1

1 study
  1. Chronic kidney disease is associated with CD4+CD28null T cells in CKD stage 5 patients undergoing peritoneal dialysis (p < 0.001).

    “Instead, CD4+CD28null frequency was increased (p < 0.001), especially in those with vascular calcifications.”

    Humansin CKD stage 5 patients undergoing peritoneal dialysis

    Novel Immune Cell Subsets Exhibit Different Associations With Vascular Outcomes in Chronic Kidney Disease Patients-Identifying Potential Biomarkers

    Frontiers in medicine

More on Chronic kidney disease

Early acute allograft rejection

downin humans1HR 0.65

1 study
  1. CD4+CD28null T cells are linked with a lower risk of early acute allograft rejection in humans (multivariate Cox regression analysis) (HR: 0.65, p = 0.028).

    “higher CD4+CD28null T-cell numbers was associated with a lower risk for EAR (HR: 0.65, p = 0.028).”

    Humansmultivariate Cox regression analysisn = 222

    Loss of CD28 on Peripheral T Cells Decreases the Risk for Early Acute Rejection after Kidney Transplantation

    PloS one

More on Early acute allograft rejection

Latest